Exelixis, Inc. (NASDAQ:EXEL) Director Sells $425,884.80 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Exelixis Trading Up 5.0 %

NASDAQ EXEL opened at $36.85 on Friday. The business’s 50 day moving average is $34.20 and its two-hundred day moving average is $31.23. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $37.59. The stock has a market capitalization of $10.31 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exelixis

Several institutional investors have recently modified their holdings of EXEL. Invesco Ltd. boosted its stake in shares of Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Norges Bank purchased a new stake in Exelixis in the 4th quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec lifted its stake in Exelixis by 330.4% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock valued at $82,730,000 after buying an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Exelixis by 104.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after buying an additional 1,613,482 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EXEL. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. Brookline Capital Management began coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. UBS Group lifted their target price on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Stephens restated an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.